Lexicon Pharmaceuticals (LXRX) Capital Expenditures (2010 - 2024)
Lexicon Pharmaceuticals (LXRX) posted quarterly Capital Expenditures of $474000.0 for Q4 2024, up 54.4% quarter-over-quarter from $307000.0 in Q3 2024.
Lexicon Pharmaceuticals (LXRX) Capital Expenditures (2010 - 2024) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Capital Expenditures for 15 consecutive years, with $474000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Capital Expenditures changed N/A year-over-year to $474000.0; the TTM figure through Dec 2025 stood at $781000.0 (down 24.25% YoY), while the FY2024 annual figure was $1.0 million, up 119.36% from the prior year.
- Capital Expenditures rose to $474000.0 in Q4 2024 per LXRX's latest filing, from $307000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.2 million in Q4 2022 and bottomed at $4000.0 in Q3 2022.
- Historically, Capital Expenditures has averaged $275666.7 across 5 years, with a median of $139000.0 in 2023.
- On a YoY basis, Capital Expenditures climbed as much as 5317.39% in 2022 and fell as far as 98.12% in 2022.
- Lexicon Pharmaceuticals' Capital Expenditures stood at $54000.0 in 2020, then sank by 57.41% to $23000.0 in 2021, then surged by 5317.39% to $1.2 million in 2022, then sank by 93.34% to $83000.0 in 2023, then surged by 471.08% to $474000.0 in 2024.
- Business Quant data shows LXRX's Capital Expenditures at $474000.0 in Q4 2024, $307000.0 in Q3 2024, and $250000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 474,000.00 |
| Dec 31, 2024 | 474,000.00 |
| Sep 30, 2024 | 307,000.00 |
| Sep 30, 2024 | 307,000.00 |
| Jun 30, 2024 | 250,000.00 |
| Jun 30, 2024 | 250,000.00 |
| Sep 30, 2023 | 83,000.00 |
| Sep 30, 2023 | 83,000.00 |
| Jun 30, 2023 | 139,000.00 |
| Jun 30, 2023 | 139,000.00 |
| Mar 31, 2023 | 248,000.00 |
| Mar 31, 2023 | 248,000.00 |
| Dec 31, 2022 | 1.25 Mn |
| Dec 31, 2022 | 1.25 Mn |
| Sep 30, 2022 | 4,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Mar 31, 2022 | 76,000.00 |
| Mar 31, 2022 | 76,000.00 |
| Dec 31, 2021 | 23,000.00 |
| Dec 31, 2021 | 23,000.00 |